Scinai Immunotherapeutics
SCNI
5 hedge funds and large institutions have $164K invested in Scinai Immunotherapeutics in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
17% less funds holding
Funds holding: 6 → 5 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
55% less capital invested
Capital invested by funds: $367K → $164K (-$203K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$5.15K |
| 2 |
Morgan Stanley
New York
|
+$1.47K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$177K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$83K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.21K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VIA
1
Vantage Investment Advisors
State College,
Pennsylvania
| $149K | – | – | – |
|
|
2
Wells Fargo
San Francisco,
California
| $6K | +$5.15K | +7 | New |
|
|
3
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $5K | -$2.21K | -3 | -33% |
|
|
EWM
4
Edge Wealth Management
New York
| $2K | – | – | – |
|
|
5
Morgan Stanley
New York
| $2K | +$1.47K | +2 | New |
|
|
6
Citadel Advisors
Miami,
Florida
| – | -$177K | -306 | Closed |
|
|
7
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$83K | -142 | Closed |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| – | -$1K | -1 | Closed |
|
SCNI Hedge Fund Activity: Q2 2017 in Review
5 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2017, worth a combined $164K — down 55% from $367K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SCNI and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest buyer was Wells Fargo, opening a new position worth an estimated $5.15K. The largest seller was Citadel Advisors, exiting entirely with an estimated $177K sold.
- 5 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2017, down from 6 in Q1 2017.
- Funds reported $164K of Scinai Immunotherapeutics stock for Q2 2017, down 55% quarter-over-quarter.
- 2 funds opened new Scinai Immunotherapeutics positions in Q2 2017 and 3 closed out, a net change of -1 holder.
- The largest Scinai Immunotherapeutics buyer in Q2 2017 was Wells Fargo, an estimated $5.15K added.
- The largest Scinai Immunotherapeutics seller in Q2 2017 was Citadel Advisors, an estimated $177K sold.
Based on aggregated 13F filings for Q2 2017.